Vancouver, British Columbia – November 01, 2021 – Blackhawk Growth Corp. (CSE:BLR, Frankfurt:0JJ)) (the "Corporation" or "Blackhawk"), is pleased to announce that MindBio Therapeutics Pty Ltd ("MindBio") is working to expand its microdosing clinical trials. MindBio is a multi-disciplinary company pioneering new treatments for mental health conditions using psychedelic medicines, technology assisted mental health interventions and psychedelic assisted psychotherapies.
MindBio is currently undertaking a world's first clinical trial of its kind. In its phase 1 clinical trial microdosing LSD (Lysergic Acid Diethylamide), MindBio is microdosing LSD to 80 healthy participants who take the drug at home in the same way that they would take any other medication. MindBio will lead phase 2 clinical trials microdosing LSD to patients with major depressive disorder and in patients with late-stage cancer - with those trials set to begin in mid-2022.
Pre-clinical research has demonstrated that psychedelic substances, including LSD, psilocybin, ayahuasca and DMT, affect neuroplasticity after acute and chronic administration. The data generated from in-vitro studies conducted by the Beckley Foundation1 demonstrated neuroplasticity by the presence of Brain Derived Neurotropic Factor (BDNF) in blood plasma. Studies conducted at the University of California, Davis2 have also shown that microdosing psychedelics such as LSD and psilocybin promote increased neurite growth, spine density and synaptogenesis.
MindBio is currently assessing natural psilocybin and potential analogs as a candidate for phase 1 microdosing clinical trials. The company can scale microdosing clinical trials to other substances quickly and cost effectively. MindBio is seeking advice on designing the clinical trial protocols given the potential for psilocybin to treat a number of mental health conditions such as major depressive disorder, PTSD and anxiety.
In addition, Blackhawk's CEO, Frederick Pels, will be contributing to the psychedelics microdosing discussions at the upcoming Wonderland convention in Miami, where MindBio is a Gold Sponsor. The event is being promoted by conference organiser Microdose as "the biggest psychedelics business event, ever".
1.https://www.beckleyfoundation.org/2018/06/13/psychedelics-promote-neural-plasticity/
2.https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30755-1
About Blackhawk Growth
Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.
The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk group supporter's telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.
For further information please contact:
Frederick Pels, Chief Executive Officer
(403)-991-7737
fred@blackhawkgrowth.com
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company's public filings under the Company's SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
Copyright (c) 2021 TheNewswire - All rights reserved.
不列顛哥倫比亞省温哥華-2021年11月1日-Blackhawk Growth Corp.(CSE:BLR,Frankfurt:0JJ)(The“公司“或”黑鷹),很高興地宣佈MindBio Treateutics Pty Ltd(MindBio“)正在努力擴大其微劑量臨牀試驗。MindBio是一家多學科公司,利用迷幻藥物、技術輔助的心理健康幹預和迷幻輔助的心理療法,開創治療精神健康疾病的新療法。
MindBio目前正在進行世界上首個此類臨牀試驗。在其微劑量LSD(賴氨酸二乙酰胺)的第一階段臨牀試驗中,MindBio公司正在向80名健康的參與者微劑量使用LSD,這些參與者在家中服用這種藥物的方式與他們服用任何其他藥物的方式相同。MindBio將領導向患有嚴重抑鬱障礙的患者和晚期癌症患者微劑量服用LSD的第二階段臨牀試驗-這些試驗將於2022年年中開始。
臨牀前研究表明,迷幻物質,包括LSD、裸蓋菇素、阿瓦斯卡和DMT,在急性和慢性給藥後都會影響神經可塑性。由貝克利基金會進行的體外研究產生的數據1 血漿中腦源性神經營養因子(BDNF)的存在證明瞭神經可塑性。在加州大學戴維斯分校進行的研究2研究還表明,微量迷幻劑(如LSD和裸蓋菇素)可促進軸突生長、脊椎密度和突觸形成。
MindBio目前正在評估天然裸蓋菇素和潛在的類似物作為第一階段微劑量臨牀試驗的候選藥物。該公司可以快速、經濟有效地將微劑量臨牀試驗擴展到其他物質。考慮到裸蓋菇素有可能治療一系列精神健康疾病,如嚴重抑鬱障礙、創傷後應激障礙和焦慮,MindBio正在尋求設計臨牀試驗方案的建議。
此外,BlackHawk的首席執行官Frederick Pels將在即將在邁阿密舉行的仙境大會上為迷幻藥物微劑量的討論做出貢獻,MindBio是該大會的金牌贊助商。會議組織者正在宣傳這項活動。微劑量被譽為“有史以來最大的迷幻商業盛會”。
1.https://www.beckleyfoundation.org/2018/06/13/psychedelics-promote-neural-plasticity/
2.https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30755-1
關於黑鷹成長
黑鷹是一家投資控股公司,希望通過收購和發展高增長公司為其股東創造實質性價值。該公司將投資重點放在加拿大和美國的健康、大麻和大麻二醇行業。它的公司組合包括SAC製藥公司、LeichtMind診所、Noble Hemp公司、Spaced Food公司、NuWave食品公司和MindBio治療公司。黑鷹繼續將其投資轉化為現金流,並正在以超乎尋常的速度增長。
該公司勤奮地通過公司Youtube官方頻道https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A的視頻發佈最新消息
請在https://t.me/Blackhawkgrowthcorp上加入我們的黑鷹團體支持者電報羣的對話並在線訪問我們的網站Https://www.blackhawkgrowth.com.
如需更多信息,請聯繫:
首席執行官弗雷德裏克·佩爾斯(Frederick Pels)
(403)-991-7737
弗雷德@Blackhawkgrowth.com
關於前瞻性陳述的注意事項
本新聞稿中的所有聲明,除歷史事實的陳述是適用證券法所指的與公司有關的“前瞻性信息”,包括與MindBio治療有限公司的交易和未來業務有關的信息。公司提供前瞻性陳述的目的是傳達有關當前對未來的預期和計劃的信息,請讀者注意,此類陳述可能不適用於其他目的。就其性質而言,這些信息受固有風險和不確定性的影響,這些風險和不確定性可能是一般性或具體性的,並可能導致預期、預測或結論被證明不準確,假設可能不正確,目標、戰略目標和優先事項無法實現。這些風險和不確定因素包括但不限於公司在www.sedar.com的SEDAR簡介中確認並在公司的公開申報文件中報告的風險和不確定性。儘管公司試圖找出可能導致實際行動、事件或結果與前瞻性信息中描述的大不相同的重要因素,但也可能有其他因素導致行動、事件或結果與預期、估計或預期的不同。不能保證這些信息將被證明是準確的,因為實際結果和未來事件可能與此類聲明中預期的大不相同。除非法律要求,否則公司不會因為新信息、未來事件或其他原因而更新或修改任何前瞻性信息,也不承擔任何義務。
版權所有(C)2021 TheNewswire-保留所有權利。